Anhui Kedgene Biotechnology

Main focus: Next generation T cell based therapies

Company stage: Clinical

Diseases: Solid tumors

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Anhui, China


Anhui Kedgene Biotechnology develops next generation T cell based therapies for solid tumor treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimize efficiacy and safety.


HashtagAnhui Kedgene Biotechnology Co.,Ltd

Search CRISPR Medicine